Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $35.82.
A number of equities research analysts have recently weighed in on ACAD shares. Mizuho cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $39.00 to $25.00 in a report on Tuesday, March 12th. Oppenheimer reaffirmed a “market perform” rating and set a $25.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, February 5th. Morgan Stanley cut their price target on ACADIA Pharmaceuticals from $40.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 13th. JMP Securities reaffirmed a “market outperform” rating and set a $42.00 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday, February 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $37.00 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday, April 10th.
Get Our Latest Stock Analysis on ACADIA Pharmaceuticals
Insiders Place Their Bets
Hedge Funds Weigh In On ACADIA Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. WCM Investment Management LLC purchased a new position in ACADIA Pharmaceuticals during the 1st quarter worth approximately $5,215,000. Wesbanco Bank Inc. purchased a new position in ACADIA Pharmaceuticals during the 1st quarter worth approximately $496,000. Diversified Trust Co grew its position in ACADIA Pharmaceuticals by 6.3% during the 1st quarter. Diversified Trust Co now owns 30,865 shares of the biopharmaceutical company’s stock worth $571,000 after purchasing an additional 1,826 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its position in ACADIA Pharmaceuticals by 24.2% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 142,998 shares of the biopharmaceutical company’s stock worth $2,644,000 after purchasing an additional 27,871 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in ACADIA Pharmaceuticals by 3.5% during the 1st quarter. Los Angeles Capital Management LLC now owns 67,474 shares of the biopharmaceutical company’s stock worth $1,248,000 after purchasing an additional 2,295 shares in the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.
ACADIA Pharmaceuticals Stock Up 2.5 %
Shares of ACAD stock opened at $16.71 on Friday. The business has a 50 day moving average of $20.11 and a two-hundred day moving average of $23.58. ACADIA Pharmaceuticals has a 52 week low of $16.16 and a 52 week high of $33.99. The company has a market cap of $2.75 billion, a P/E ratio of -43.97 and a beta of 0.37.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last issued its earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. The company had revenue of $231.04 million during the quarter, compared to analyst estimates of $223.79 million. During the same quarter in the previous year, the firm earned ($0.26) earnings per share. The business’s revenue was up 69.3% on a year-over-year basis. Analysts expect that ACADIA Pharmaceuticals will post 0.62 EPS for the current fiscal year.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
See Also
- Five stocks we like better than ACADIA Pharmaceuticals
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Stocks Leading the U.S. Agriculture Comeback
- The How And Why of Investing in Oil Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Insider Buying Explained: What Investors Need to Know
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.